1317 ET - Hims & Hers is hoping to take advantage of an FDA rule to be able to keep selling compounded versions of weight-loss drugs, even after the GLP-1 shortage has ended, Needham analyst Ryan MacDonald tells WSJ. The personalization exemption rule allows companies to sell compounds if they are personalizing the treatment for a patient; for example, if the patient needs to take an oral form instead of an injection. Hims hopes it can keep offering personalized compounds, as compounded drugs make up a significant portion of its weight-loss revenue, MacDonald says. But if the FDA finds this illegal, the company may be challenged to meet revenue goals, MacDonald says. (katherine.hamilton@wsj.com)
(END) Dow Jones Newswires
April 02, 2025 13:17 ET (17:17 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.